Production of antibodies and antibody fragments in Escherichia coli and a comparison of their functions, uses and modification - PubMed

Affiliations

• PMID: 12669454

Review

Production of antibodies and antibody fragments in Escherichia coli and a comparison of their functions, uses and modification

David P Humphreys. Curr Opin Drug Discov Devel. 2003 Mar.

Abstract

Antibody-based drugs are now used in the clinic, and their importance as therapeutics is expected to increase in the coming decade, both in terms of diseases treated and market value. However, the proportion of patients that can be treated is to some extent affected by the availability and cost of the therapeutic. Therefore, the means of production and purification of the therapeutic entity, as well as the type of therapeutic entity, are of great concern. Escherichia coli represents a good production host in terms of scale and speed of production, but it also has technical and biological limitations. The aim of this review is to describe and discuss the relative benefits and limitations of E coli as a host for the production of antibodies and engineered antibody fragments.

Similar articles

• Prokaryotic expression of antibodies.

  Arbabi-Ghahroudi M, Tanha J, MacKenzie R. Arbabi-Ghahroudi M, et al. Cancer Metastasis Rev. 2005 Dec;24(4):501-19. doi: 10.1007/s10555-005-6193-1. Cancer Metastasis Rev. 2005. PMID: 16408159 Review.

• Functional expression of single-chain variable fragment antibody against c-Met in the cytoplasm of Escherichia coli.

  Heo MA, Kim SH, Kim SY, Kim YJ, Chung J, Oh MK, Lee SG. Heo MA, et al. Protein Expr Purif. 2006 May;47(1):203-9. doi: 10.1016/j.pep.2005.12.003. Epub 2005 Dec 28. Protein Expr Purif. 2006. PMID: 16414274

• Expression of monovalent and bivalent antibody fragments in Escherichia coli.

  Grant SD, Cupit PM, Learmonth D, Byrne FR, Graham BM, Porter AJ, Harris WJ. Grant SD, et al. J Hematother. 1995 Oct;4(5):383-8. doi: 10.1089/scd.1.1995.4.383. J Hematother. 1995. PMID: 8581373

• Comparison of techniques for monitoring antibody fragment production in E. coli fermentation cultures.

  Bowering LC, Bracewell DG, Kesharvarz-Moore E, Hoare M, Weir AN. Bowering LC, et al. Biotechnol Prog. 2002 Nov-Dec;18(6):1431-8. doi: 10.1021/bp0201152. Biotechnol Prog. 2002. PMID: 12467481

• Production technologies for monoclonal antibodies and their fragments.

  Andersen DC, Reilly DE. Andersen DC, et al. Curr Opin Biotechnol. 2004 Oct;15(5):456-62. doi: 10.1016/j.copbio.2004.08.002. Curr Opin Biotechnol. 2004. PMID: 15464378 Review.

Cited by

• APEx 2-hybrid, a quantitative protein-protein interaction assay for antibody discovery and engineering.

  Jeong KJ, Seo MJ, Iverson BL, Georgiou G. Jeong KJ, et al. Proc Natl Acad Sci U S A. 2007 May 15;104(20):8247-52. doi: 10.1073/pnas.0702650104. Epub 2007 May 9. Proc Natl Acad Sci U S A. 2007. PMID: 17494738 Free PMC article.

• Solubility, Stability, and Avidity of Recombinant Antibody Fragments Expressed in Microorganisms.

  Kang TH, Seong BL. Kang TH, et al. Front Microbiol. 2020 Sep 25;11:1927. doi: 10.3389/fmicb.2020.01927. eCollection 2020. Front Microbiol. 2020. PMID: 33101218 Free PMC article. Review.

• Comprehensive engineering of Escherichia coli for enhanced expression of IgG antibodies.

  Makino T, Skretas G, Kang TH, Georgiou G. Makino T, et al. Metab Eng. 2011 Mar;13(2):241-51. doi: 10.1016/j.ymben.2010.11.002. Epub 2010 Dec 3. Metab Eng. 2011. PMID: 21130896 Free PMC article.

• Broad-host-range plasmid pJB658 can be used for industrial-level production of a secreted host-toxic single-chain antibody fragment in Escherichia coli.

  Sletta H, Nedal A, Aune TE, Hellebust H, Hakvåg S, Aune R, Ellingsen TE, Valla S, Brautaset T. Sletta H, et al. Appl Environ Microbiol. 2004 Dec;70(12):7033-9. doi: 10.1128/AEM.70.12.7033-7039.2004. Appl Environ Microbiol. 2004. PMID: 15574897 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Other Literature Sources

  • The Lens - Patent Citations Database